Literature DB >> 10792488

Renal lesions in von Hippel-Lindau disease: immunohistochemical expression of nephron differentiation molecules, adhesion molecules and apoptosis proteins.

F Paraf1, D Chauveau, Y Chrétien, S Richard, J P Grünfeld, D Droz.   

Abstract

AIMS: Renal lesions in von Hippel-Lindau disease comprise clear cell simple cysts, atypical cysts and carcinomas. Although histological and molecular studies suggest that cystic lesions may represent precursors of carcinomas, there is no detailed phenotypic evidence of their relationship. METHODS AND
RESULTS: To investigate such a possible relationship between cystic lesions and solid carcinomas, we studied the pathological and immunohistochemical features of 328 lesions of 33 kidneys originating from 23 patients with von Hippel-Lindau disease, using a panel of antibodies directed against cytoskeleton proteins, cell surface proteins, integrin subunits, adhesion molecules, lectins, and apoptosis and proliferation markers. Solid carcinomas (n = 175) were all of clear cell type and mostly nuclear grade 1. Cystic lesions (n = 138) consisted of cystic clear cell carcinomas (n = 15), atypical cysts (n = 20) and simple cysts (n = 103). Clear cells of the simple cysts, atypical cysts and solid carcinomas coexpressed cytokeratins (CK8, CK19) and vimentin, and expressed a similar pattern of tubular markers (CD24, tetraglonolobus), integrin subunits (alpha3, alpha5, alpha6, alphav, beta1) and cell adhesion molecules (ICAM 1, VCAM 1). In all lesions studied, proliferation rate (MIB1 index) was low, and apoptosis marker expression (fragmented DNA, p53, bcl-2) inconspicuous.
CONCLUSIONS: Phenotypic alterations found in solid renal cell carcinomas are already present in simple and atypical renal cysts of von Hippel-Lindau disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792488     DOI: 10.1046/j.1365-2559.2000.00857.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  12 in total

1.  Downregulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation.

Authors:  Qingzhou Ji; Robert D Burk
Journal:  Biochem Cell Biol       Date:  2008-06       Impact factor: 3.626

2.  VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling.

Authors:  E J Davidowitz; A R Schoenfeld; R D Burk
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

3.  Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis.

Authors:  Shan-Shan Wang; Yi-Feng Gu; Nicholas Wolff; Karoliina Stefanius; Alana Christie; Anwesha Dey; Robert E Hammer; Xian-Jin Xie; Dinesh Rakheja; Ivan Pedrosa; Thomas Carroll; Renée M McKay; Payal Kapur; James Brugarolas
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-30       Impact factor: 11.205

Review 4.  Von Hippel-Lindau Disease.

Authors:  Jennifer J Findeis-Hosey; Kelly Q McMahon; Sarah K Findeis
Journal:  J Pediatr Genet       Date:  2016-04-04

5.  Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor.

Authors:  Erinn B Rankin; John E Tomaszewski; Volker H Haase
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

6.  Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium.

Authors:  Kim Margolin; Timothy W Synold; Primo Lara; Paul Frankel; Simon F Lacey; David I Quinn; Tracey Baratta; Janice P Dutcher; Bixin Xi; Don J Diamond; David R Gandara
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-17       Impact factor: 4.553

7.  Von Hippel-Lindau syndrome and renal tumours: radiological diagnostic and treatment options. A case report and literature review.

Authors:  Audrius Untanas; Mantas Trakymas; Indrė Lekienė; Rūta Briedienė
Journal:  Acta Med Litu       Date:  2020

8.  HIF-2alpha downregulation in the absence of functional VHL is not sufficient for renal cell differentiation.

Authors:  Michael D Hughes; Erilda Kapllani; Ashlynn E Alexander; Robert D Burk; Alan R Schoenfeld
Journal:  Cancer Cell Int       Date:  2007-06-28       Impact factor: 5.722

9.  Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Authors:  Valentina Bangiyeva; Ava Rosenbloom; Ashlynn E Alexander; Bella Isanova; Timothy Popko; Alan R Schoenfeld
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

Review 10.  Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.

Authors:  Eric Jonasch; Cheryl Lyn Walker; W Kimryn Rathmell
Journal:  Nat Rev Nephrol       Date:  2020-11-03       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.